Engflag

Kostarox

Quick links to important sections

Kostarox

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kostarox

Kostarox is a prescription-only, synthetic pharmaceutical product administered in the form of a film-coated tablet for oral use. Its identity is established by its sole active component, Etoricoxib, which is the internationally recognized nonproprietary name for the substance.

Property Description
Active ingredient Etoricoxib
Form Film-coated tablets
Pharmacological class Selective Cyclooxygenase-2 (COX-2) Inhibitor
Common use Symptomatic relief of pain and inflammation
Origin Synthetic

Identity: The Active Ingredient and Form

The core of Kostarox is the highly potent chemical substance Etoricoxib, which is delivered to the body via a solid pharmaceutical excipient within the tablet vehicle. The drug’s composition, as a single-ingredient product, means its therapeutic effects are derived exclusively from the Etoricoxib component. Kostarox specifically targets the management of symptoms in patients aged 16 and over and is clinically recognized for its efficacy in providing sustained relief.

Classification: The Selective COX-2 Inhibitor Type

Kostarox is formally categorized as a Selective Cyclooxygenase-2 (COX-2) Inhibitor, placing it within a specific subclass of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The selective nature of this inhibition is a key characteristic of Etoricoxib, as it primarily blocks the COX-2 enzyme, which is responsible for synthesizing chemical mediators of inflammation and pain known as prostaglandins. This mechanism results in a dual action—providing both an anti-inflammatory effect and an analgesic effect. The overall general therapeutic purpose of Kostarox is the symptomatic relief of acute or chronic discomfort, such as the pain and swelling experienced during periods of acute musculoskeletal inflammation.

Regulatory References

  1. EMA Etoricoxib Assessment Report (Arcoxia)

What side effects are possible with Kostarox?

Possible Side Effects and Safety Information

The safety profile of Kostarox (Etoricoxib) is formalized by regulatory authorities, with potential adverse reactions classified by frequency and grouped into affected organ systems. This medicine carries risks common to its class, the selective Cyclooxygenase-2 (COX-2) inhibitors, including the potential for serious cardiovascular thrombotic events, such as myocardial infarction and stroke, and serious gastrointestinal complications like ulcers or haemorrhage.

Frequency-Classified Adverse Reactions

The official documentation categorizes adverse effects based on their frequency of occurrence:

  • Common (affecting 1 to 10 users in 100): Includes systemic effects like oedema/fluid retention and hypertension, and gastrointestinal effects such as dyspepsia, abdominal pain, and flatulence. Nervous system effects like headache and dizziness are also common.
  • Uncommon (affecting 1 to 10 users in 1,000): Covers events such as palpitations, congestive heart failure, and episodes of atrial fibrillation.
  • Rare and Very Rare: These include severe systemic responses like hypersensitivity reactions, hepatic failure, and life-threatening skin conditions such as Stevens-Johnson Syndrome.

Safety-Related Restrictions and Patterns

The risk of serious cardiovascular events is officially noted to increase with both the dose and the duration of Etoricoxib exposure. The risk of serious gastrointestinal events is higher in older adults. Furthermore, use is contraindicated in patients with established ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, uncontrolled hypertension, or severe hepatic impairment, as documented in official regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official information for Kostarox (Etoricoxib) overdose mandates immediate action and outlines specific, documented clinical manifestations and potential severe outcomes.

Feature Official Regulatory Statement
Documented Presentations Overdose has primarily presented with an exaggeration of known effects, including nausea, vomiting, dyspepsia, and abdominal pain.
Severe Outcomes There is a potential for acute renal failure and serious gastrointestinal adverse events, such as hemorrhage, particularly in severe exposure cases.
Antidote Availability No specific antidote is known or available to reverse the effects of Etoricoxib overdose.

Immediate Emergency Action

In the event of a suspected overdose, the most critical action is to seek immediate medical attention or contact emergency services, as strictly required by regulatory guidance. Since no specific antidote exists, the mandated clinical management is entirely symptomatic and supportive treatment.

The drug’s relatively long elimination half-life, which is approximately 20 hours, dictates the necessity for prolonged clinical status monitoring within a healthcare setting, independent of the severity of initial symptoms. Patients with compromised renal function are noted to be at an increased risk of severe renal effects following overdose. This framework is based entirely on the documented clinical findings and the procedural response defined by regulatory authorities to manage the risks of potential systemic toxicity.

Therapeutic Uses of Kostarox

Kostarox (Etoricoxib) is applied across domains where additional symptomatic support is needed, primarily focusing on symptoms related to inflammatory or irritative states that interfere with daily functioning. This includes easing the overall symptom burden in specific chronic and acute conditions.

The medication is commonly used across conditions characterized by periods of heightened symptoms such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also relevant in clinical settings that involve acute or unstable symptom patterns, including sudden flare-ups of Acute Gouty Arthritis, localized moderate pain associated with dental surgery, and recurrent or episodic manifestations like Primary Dysmenorrhea.

The medication offers supportive relief when symptoms become temporarily overwhelming, assisting with managing symptoms that interfere with daily functioning during difficult episodes.

“It is commonly used to help address symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort.”

Quick Fact: Focus on managing Inflammation and Joint Pain

Regulatory References

  1. Medicines and Healthcare products Regulatory Agency (MHRA)

Eligibility and Restrictions for Use

Who can and cannot use Kostarox?

Official regulatory documents strictly define the population groups eligible to use Kostarox (Etoricoxib), primarily indicating use for adults and adolescents 16 years of age and older. The medicine is contraindicated (must not be used) in patients with specific severe medical conditions or physiological states.

Contraindicated Populations Restricted/Limited Use
Cardiovascular: Established Ischaemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease (stroke/TIA), or Congestive Heart Failure (NYHA II–IV). Moderate Hepatic Impairment (Child-Pugh score 7–9)
Hypertension: Persistently elevated blood pressure above 140/90 mmHg and inadequately controlled. Renal Impairment (Creatinine Clearance 30 ml/min) requires caution and monitoring.
GI Health: Active peptic ulceration, active GI bleeding, or Inflammatory Bowel Disease. Elderly Patients (use requires appropriate medical supervision).
Organ Failure: Severe hepatic dysfunction (Child-Pugh score 10) or severe renal impairment (Creatinine Clearance < 30 ml/min) Women Attempting to Conceive (use is not recommended).
Pregnancy/Lactation: Use is contraindicated during both pregnancy and breastfeeding.
Age: Children and adolescents under 16 years of age are contraindicated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Kostarox (Etoricoxib) has officially documented interaction patterns that span pharmacokinetic and pharmacodynamic domains, requiring specific restrictions on co-administration, as stated in regulatory labeling.

Contraindicated Combinations

Co-administration is formally prohibited with all other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Selective COX-2 Inhibitors. Use with Acetylsalicylic acid (Aspirin) at doses above those used for low-dose cardiovascular prophylaxis is not recommended due to an increased risk of gastrointestinal adverse effects.

Exposure-Modifying Interactions

Etoricoxib co-administration has a documented effect on the plasma exposure of several concomitant medicines. It is officially stated to increase the steady-state plasma concentrations (AUC) of both Ethinyl Estradiol (a component of oral contraceptives) and Lithium. Etoricoxib may also increase plasma levels of Methotrexate, particularly with doses greater than 90 mg daily. Conversely, co-administration with strong inducers of hepatic metabolism, such as Rifampin, can result in a significant decrease in Etoricoxib plasma exposure.

Pharmacodynamic and Renal Function Interactions

When combined with Warfarin or other oral anticoagulants, there is a documented increase in the International Normalized Ratio (INR), which raises the risk of bleeding. The antihypertensive and natriuretic effects of Diuretics, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs) may be diminished by co-administration. This combination is noted to carry an increased risk of renal function deterioration, particularly in elderly and volume-depleted patient populations. Administration with food alters the rate of absorption but is not considered a clinically significant restriction.

Mechanism of Action

Enzyme-Mediated Signaling Modulation

Kostarox operates within domains involving enzyme-mediated signaling through the selective and reversible inhibition of cyclooxygenase-2 ( COX-2). This mechanistic cascade modifies an early molecular step: the biosynthesis of pro-inflammatory prostaglandins. This action regulates the downstream signaling pathways responsible for initiating inflammatory processes.

Modulation of Inflammatory Mediator Production

The compound alters pathway activity through the suppression of prostaglandin synthesis. This inhibitory action results in a reduction of pro-inflammatory signaling due to the decreased concentration of eicosanoid transmitters. This modulation affects biological systems where these specific mediators dominate the inflammatory cascade.

Modification of Nociceptor Sensitization

Kostarox engages mechanisms that regulate prostaglandin-dependent signaling within peripheral tissues. By reducing local prostaglandin levels, the mechanism alters nociceptor sensitivity and signaling output. This results in decreased activation of peripheral nociceptive pathways, modulating the transmission of afferent signals.

Dosage and Administration Information

Kostarox (Etoricoxib) is administered by the oral route, consistent with its form as a film-coated tablet. The medication is scheduled for once daily use across all approved indications. Dosing is specific to the condition being addressed.

Dosing and Regimen Standards

For chronic symptomatic relief, such as in Rheumatoid Arthritis and Ankylosing Spondylitis, the standard dose typically starts at 60 mg and may be adjusted to a maximum of 90 mg once daily. For acute episodes, the medicine is used for short, defined periods. The dose for Acute Gouty Arthritis is 120 mg once daily, but this treatment is limited to a maximum of eight days. Use for acute pain following dental surgery is 90 mg once daily, with a maximum duration of three days.

Administration Conditions and Restrictions

For proper administration, the tablet may be taken with or without food; administration without food may allow for a faster onset of action. The overall protocol for chronic uses involves using the lowest effective dose for the shortest duration necessary. Dosage adjustments apply for specific populations: patients with mild hepatic impairment have a maximum daily dose limit of 60 mg, and those with moderate hepatic impairment are restricted to a maximum of 30 mg once daily. The use of Etoricoxib is for individuals aged 16 years and older.

Recent Clinical Evidence

Kostarox: Recent Clinical Evidence

The research for Kostarox (Etoricoxib) has consistently focused on evaluating symptomatic changes in conditions characterized by pain and functional limitations, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA).

Evidence for Chronic Conditions

Large-scale randomized controlled trials (RCTs) examined how symptoms related to physical discomfort and daily functioning changed over time in adults with OA and RA. Studies report patterns observed in patient-reported outcomes, often showing changes in pain scores and joint function metrics over short- to intermediate-term follow-up (up to 52 weeks or longer in extensions).

For acute, episodic conditions like Acute Gouty Arthritis, research explored short-term symptom changes, focusing on pain reduction and swelling over limited durations, typically less than 10 days. Similar short-term studies examined pain relief following Dental Surgery and during Primary Dysmenorrhea.

Long-Term Safety and Limitations

Extended-duration studies, including large comparative programs, have primarily monitored the long-term safety profile, specifically tracking cardiovascular and gastrointestinal events. These studies provide context for the evolution of adverse events but offer limited information on the sustained evolution of symptomatic change and outcomes reflecting daily functioning over many years.

Research has explored the drug's use in adult cohorts, including older adults and the extreme elderly in some OA studies. However, evidence remains limited regarding the long-term outcomes and dedicated efficacy data for certain subgroups or in patients with specific comorbid conditions. Comparative evidence against the full range of traditional pain relievers is an area where data are still emerging.

Key Studies & References

  1. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

Frequently Asked Questions (FAQ)

Common questions about Kostarox (FAQ)

Q: What is Kostarox used for?

Kostarox has received regulatory indication approval for the management of mild to moderate pain and inflammation associated with osteoarthritis.

Q: How does Kostarox work?

Kostarox belongs to a class of medications called non-steroidal anti-inflammatory drugs (NSAIDs). It is understood to exert its effect by temporarily inhibiting certain substances in the body that contribute to pain and swelling.

Q: What is the typical dosage for Kostarox?

The appropriate dosage and administration schedule for Kostarox are determined solely by a qualified healthcare provider based on the individual's medical condition and response to therapy. Patients should follow the specific directions given by their doctor.

Q: How quickly does Kostarox start working?

Based on clinical study observations, some patients may notice initial effects within a few hours of the first dose. However, the timeframe for feeling a notable benefit may vary significantly among individuals.

Q: Is Kostarox safe for long-term use?

Long-term use of any medication should be discussed in detail with a healthcare professional, who will weigh the potential benefits against the risks. Ongoing treatment requires regular medical monitoring.

How should Kostarox be stored and disposed of?

How to Store and Dispose of Kostarox?

The safe storage and handling of Kostarox (Etoricoxib) must adhere strictly to official regulatory guidelines to maintain product stability and integrity.

Storage Conditions

Kostarox tablets must be stored at a temperature below 30°C. It is mandatory to keep the medicine in the original packaging (blister pack or outer carton) to ensure protection from moisture. All medicinal products, including Kostarox, must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Kostarox must be carried out according to local requirements for pharmaceutical waste. The medicine must not be discarded via wastewater or general household trash to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Kostarox found in:

A-Z Index: